Compare Adaptive Biotechnologies Corp (ADPT) vs Adecoagro SA (AGRO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Adecoagro SA — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Adecoagro SA trades at $10.12 (market cap $1.39B). The key difference: Adaptive Biotechnologies Corp is far larger — about 2.4× Adecoagro SA's market cap, and Adecoagro SA pays a 3.08% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | AGRO | |
|---|---|---|
Market Cap | $3.33B | $1.39B |
Sector | Health | Technology |
52-Week High | $22.37 | $15.25 |
52-Week Low | $10.24 | $7.13 |
Enterprise Value | $3.19B | $3.42B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
AGRO trades at $9.48, down 1.66% today, with a bearish technical signal despite neutral oscillators. The company reported mixed quarterly results, missing Q1 2026 EPS estimates but showing strong adjusted EBITDA growth. Valuation metrics appear attractive with P/S of 0.71 and P/B of 0.78, though profitability remains weak with a 0.91% net margin. Recent news highlights innovation in agriculture operations and a declared $0.12 dividend for H1 2026.
The stock offers value appeal with below-market multiples and analyst consensus target of $12.75 implying 34% upside. However, inconsistent earnings performance and negative net income in 2025 pose execution risks. The bearish technical trend and competitive pressures in sustainable agriculture require careful monitoring for potential investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →
